Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.61 |
| ▸ | ACE | P12821 | 3/20 | 0.56 |
| ▸ | CPA1 | P15085 | 3/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10618864 | 1.00 | MME (0.61) | MMEACECPA1ACE2NAALAD2 | |
| SCHEMBL30494635 | 1.00 | MME (0.61) | MMEACECPA1ACE2NAALAD2 | |
| SCHEMBL135367 | 1.00 | MME (0.61) | MMEACECPA1ACE2NAALAD2 | |
| SCHEMBL668395 | 1.00 | MME (0.61) | MMEACECPA1ACE2NAALAD2 | |
| SCHEMBL11548564 | 1.00 | MME (0.61) | MMEACECPA1ACE2NAALAD2 | |
| SCHEMBL135366 | 1.00 | MME (0.61) | MMEACECPA1ACE2NAALAD2 | |
| SCHEMBL8761646 | 1.00 | MME (0.61) | MMEACECPA1ACE2NAALAD2 | |
| SCHEMBL8206518 | 0.98 | MME (0.60) | MMEACECPA1ACE2NAALAD2 | |
| Water SCHEMBL27822843 | 0.98 | MME (0.60) | MMEACECPA1ACE2NAALAD2 | |
| Hydrochloric Acid SCHEMBL9136406 | 0.98 | MME (0.60) | MMEACECPA1ACE2NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329827-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | Alphathera AG (CH) | 2024-03-06 | — | — | EP | claimed |
| WO-2022231424-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | ALPHATHERA AG (CH) | 2022-11-03 | — | — | WO | claimed |
| US-20250170243-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2025-05-29 | — | — | US | disclosed |
| CN-112041328-B | Dipeptide and pharmaceutical composition containing the same | 志瑞亚新药工业株式会社 | 2024-06-21 | — | — | CN | disclosed |
| EP-4329827-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | Alphathera AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| JP-2024003144-A | Pharmaceutical composition containing dipeptide | ゼリア新薬工業株式会社 | 2024-01-11 | — | — | JP | disclosed |
| EP-4251213-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM Solucin GmbH (DE) | 2023-10-04 | — | — | EP | disclosed |
| CN-116806144-A | Stable formulations of radionuclide complexes | ITM索卢钦股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| JP-2023089192-A | DIPEPTIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ゼリア新薬工業株式会社 | 2023-06-27 | — | — | JP | disclosed |
| WO-2022231424-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | ALPHATHERA AG (CH) | 2022-11-03 | — | — | WO | disclosed |
| EP-4065176-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotope Technologies Munich SE (DE) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022112323-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM SOLUCIN GMBH (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022096673-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170243-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | SLC40A1, SLC7A11, GYPA | MME 355/4885ACE 568/4885CPA1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.